Home / Business and Economy / Gland Pharma Soars to 4-Year High on Strong Q1 Earnings
Gland Pharma Soars to 4-Year High on Strong Q1 Earnings
11 Aug
Summary
- Gland Pharma's stock reached a four-year peak, surging 12% on Tuesday.
- The company reported a 47% year-on-year profit jump to ₹317 crore for Q1FY27.
- Brokerages maintain a positive outlook, citing growth potential and capacity expansion.
Gland Pharma's stock achieved a significant milestone, reaching an over four-year high of ₹2,989.25 on Tuesday, August 11, 2026. This surge occurred despite a weak broader market and was fueled by the company's robust financial performance in the first quarter of fiscal year 2027.
The company reported a substantial 47% year-on-year increase in consolidated profit after tax (PAT), reaching ₹317 crore for the quarter ended June 2026. Revenue also saw a healthy 19.6% year-on-year growth, amounting to ₹1,800 crore. These positive results were primarily driven by strong performance in the United States and European Union markets.
Brokerage firms have responded favorably to Gland Pharma's results and future prospects. ICICI Securities highlighted beats across key parameters and noted positive EBITDA from Cenexi. The company announced plans for significant capital expenditure, over ₹2000 crore, in the next five years to expand capacity and is targeting an 18-20% compound annual growth rate.
Motilal Oswal Financial Services reiterated a 'BUY' rating, raising earnings estimates for FY27 and FY28. They anticipate a 21% earnings CAGR over FY26-28, focusing on complex injectables and advanced technologies like peptides and GLP-1. The brokerage set a target price of ₹3,080, reflecting confidence in the company's strategic growth initiatives.
